Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. We are also committed to translating immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
The Power of Immunosequencing
Learn how sequencing T- and B-cell receptors is being used to advance scientific discovery.
clonoSEQ & MRD
Learn about clonoSEQ and how it identifies and tracks measurable residual disease (MRD).
in the news
February 13, 2018
features
Learning to "read" the immune system
Microsoft and Adaptive are partnering to map the genetics of the human immune system to diagnose disease.
ADAPTIVE'S TERMS OF USE AND PRIVACY POLICIES APPLY TO THE USE OF THIS SITE
The Terms of Use, HIPAA policy, Privacy Shield Policy, and Online Privacy Policy, govern the use of this web site. Adaptive may update, change, add, or delete policies in its sole discretion without notice to you. You have an affirmative obligation to review the web site from time to time and read and understand the policies. By using this web site, you expressly agree to this.